BR112021006318A2 - terapia de combinação para o tratamento de câncer - Google Patents

terapia de combinação para o tratamento de câncer

Info

Publication number
BR112021006318A2
BR112021006318A2 BR112021006318A BR112021006318A BR112021006318A2 BR 112021006318 A2 BR112021006318 A2 BR 112021006318A2 BR 112021006318 A BR112021006318 A BR 112021006318A BR 112021006318 A BR112021006318 A BR 112021006318A BR 112021006318 A2 BR112021006318 A2 BR 112021006318A2
Authority
BR
Brazil
Prior art keywords
combination therapy
cancer treatment
combination
daratumumab
cocrystal
Prior art date
Application number
BR112021006318A
Other languages
English (en)
Inventor
Thakurta Anjan
Bjorklund Chad
Cota Mariana
D Amatangelo Michael
Hong Xiankang
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BR112021006318A2 publication Critical patent/BR112021006318A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Abstract

terapia de combinação para o tratamento de câncer. trata-se de métodos para tratar e/ou controlar cânceres que compreendem administrar a um paciente o composto a, ou um enantiômero ou uma mistura de enantiômeros do mesmo, ou um sal, solvato, hidrato, cocristal, clatrato ou polimorfo farmaceuticamente aceitável do mesmo em combinação com daratumumabe. adicionalmente, métodos para tratar e/ou controlar cânceres que compreendem administrar a um paciente o composto a, ou um enantiômero ou uma mistura de enantiômeros do mesmo, ou um sal, solvato, hidrato, cocristal, clatrato ou polimorfo farmaceuticamente aceitável do mesmo em combinação com daratumumabe e dexametasona são fornecidos no presente documento.
BR112021006318A 2018-10-01 2019-09-30 terapia de combinação para o tratamento de câncer BR112021006318A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862739809P 2018-10-01 2018-10-01
US201862773980P 2018-11-30 2018-11-30
PCT/US2019/053721 WO2020072334A1 (en) 2018-10-01 2019-09-30 Combination therapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112021006318A2 true BR112021006318A2 (pt) 2021-07-06

Family

ID=69945395

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021006318A BR112021006318A2 (pt) 2018-10-01 2019-09-30 terapia de combinação para o tratamento de câncer

Country Status (12)

Country Link
US (2) US11529339B2 (pt)
EP (1) EP3860610A4 (pt)
JP (1) JP7466549B2 (pt)
KR (1) KR20210069642A (pt)
CN (1) CN112839658A (pt)
AU (1) AU2019351811A1 (pt)
BR (1) BR112021006318A2 (pt)
CA (1) CA3114401A1 (pt)
IL (1) IL281845A (pt)
MX (1) MX2021003842A (pt)
SG (1) SG11202103141YA (pt)
WO (1) WO2020072334A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019351811A1 (en) 2018-10-01 2021-05-06 Celgene Corporation Combination therapy for the treatment of cancer
CN115315260A (zh) * 2019-12-02 2022-11-08 新基公司 治疗癌症的疗法
JP2023531512A (ja) * 2020-06-25 2023-07-24 セルジーン コーポレーション 併用療法を用いて癌を治療するための方法
WO2024064646A1 (en) 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ599199A (en) 2007-03-20 2013-10-25 Celgene Corp 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
SI3202461T1 (sl) 2010-02-11 2019-05-31 Celgene Corporation Derivati arilmetoksi izoindolina in sestavki, ki jih vsebujejo in metode uporabe le teh
KR20130038838A (ko) 2010-03-12 2013-04-18 셀진 코포레이션 레날리도미드, 및 예측 인자로서 유전자 및 단백질 바이오마커를 사용한 비호지킨 림프종의 치료 방법
EA201391319A1 (ru) 2011-03-11 2014-03-31 Селджин Корпорейшн Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона
HUE056127T2 (hu) 2012-08-09 2022-01-28 Celgene Corp A rák kezelésének módszerei 3-(4-((4-(morfolino-metil)-benzil)-oxi) -1-oxi-izo-dolin-2-il) - piperidin-2,6-dion alkalmazásával
CN104718202B (zh) 2012-08-09 2018-11-20 细胞基因公司 用于制备(s)-3-(4-((4-(吗啉基甲基)苄基)氧基)-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮及其可药用形式的方法
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
US20140343058A1 (en) 2012-08-09 2014-11-20 Celgene Corporation Treatment of systemic lupus erythematosus
PL2882441T3 (pl) 2012-08-09 2020-09-21 Celgene Corporation Leczenie chorób immunologicznych i zapalnych
EP3524598B1 (en) 2012-08-09 2021-07-07 Celgene Corporation A solid form of (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
TWI794885B (zh) 2014-05-19 2023-03-01 美商西建公司 全身紅斑性狼瘡之治療
BR112017003620A2 (pt) * 2014-08-22 2017-12-05 Celgene Corp métodos de tratamento de mieloma múltiplo com compostos imunomoduladores em combinação com anticorpos
EP3535295A1 (en) * 2016-11-02 2019-09-11 EngMab Sàrl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
AU2019351811A1 (en) 2018-10-01 2021-05-06 Celgene Corporation Combination therapy for the treatment of cancer
EA202190865A1 (ru) * 2018-11-30 2021-07-01 Селджин Корпорейшн Комбинированная терапия для лечения рака

Also Published As

Publication number Publication date
US20200101058A1 (en) 2020-04-02
US11529339B2 (en) 2022-12-20
AU2019351811A1 (en) 2021-05-06
WO2020072334A1 (en) 2020-04-09
US20230277517A1 (en) 2023-09-07
JP2022508513A (ja) 2022-01-19
CN112839658A (zh) 2021-05-25
JP7466549B2 (ja) 2024-04-12
KR20210069642A (ko) 2021-06-11
IL281845A (en) 2021-05-31
SG11202103141YA (en) 2021-04-29
EP3860610A1 (en) 2021-08-11
EP3860610A4 (en) 2022-06-15
CA3114401A1 (en) 2020-04-09
MX2021003842A (es) 2021-05-27

Similar Documents

Publication Publication Date Title
BR112021006318A2 (pt) terapia de combinação para o tratamento de câncer
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
BR112017017078A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença.
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
PH12019500214A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
BR112017023233A2 (pt) métodos para tratamento de câncer
PH12016502354A1 (en) Pharmaceutical composition
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
EP3970712A3 (en) Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
PH12016502352A1 (en) Pharmaceutical composition
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
PH12016502353A1 (en) Pharmaceutical composition
BR112019002730A2 (pt) acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
BR112019002461A2 (pt) regime de dosagem para tratamento de tumores sólidos
MX2017012123A (es) Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer.
CO2020013968A2 (es) Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
CL2018001434A1 (es) Terapia cíclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
PH12020500666A1 (en) Pladienolide compounds and their use
MX2019000413A (es) Inhibidores de triptofano 2,3-dioxigenasa.
BR112022010537A2 (pt) Terapia para o tratamento do câncer
EA202190865A1 (ru) Комбинированная терапия для лечения рака

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]